Breast cancer trials recruiting in Oklahoma

All Breast cancer trials nationally

Cities in Oklahoma

Recruiting trials in Oklahoma

• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
  NCT05932862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Tulsa
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
  NCT05894239 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• BostonGene and Exigent Genomic INsight Study
  NCT06272864 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Tulsa
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Oklahoma: Oklahoma City
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female · Oklahoma: Lawton, Oklahoma City
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
  NCT03053193 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Lawton
• Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
  NCT07014618 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
  NCT05921253 · Phase: Early Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa
• Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
  NCT01766297 · Phase: Phase 2 · Ages: 50 Years and older · Sex: Female · Oklahoma: Oklahoma City
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
  NCT03418961 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa
• S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
  NCT03723928 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Oklahoma: Tulsa
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City, Tulsa
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Lawton, Oklahoma City
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Lawton, Oklahoma City
• Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
  NCT05898399 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Study of XB010 in Subjects With Solid Tumors
  NCT06545331 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · Oklahoma: Oklahoma City
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
  NCT06500481 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Oklahoma: Oklahoma City
• The Vanguard Study: Testing a New Way to Screen for Cancer
  NCT06995898 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 75 Years · Sex: All (male and female) · Oklahoma: Oklahoma City